BIOA
BioAge Labs Inc.

433
Mkt Cap
$461.81M
Volume
327,653.00
52W High
$13.10
52W Low
$2.88
PE Ratio
-6.09
BIOA Fundamentals
Price
$12.88
Prev Close
$12.75
Open
$12.72
50D MA
$7.94
Beta
1.29
Avg. Volume
262,792.21
EPS (Annual)
-$1.98
P/B
1.66
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Paul Rubin Sells 18,000 Shares of BioAge Labs (NASDAQ:BIOA) Stock
BioAge Labs, Inc. (NASDAQ:BIOA - Get Free Report) insider Paul Rubin sold 18,000 shares of the stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
BioAge Labs (NASDAQ:BIOA) Insider Sells $216,000.00 in Stock
BioAge Labs, Inc. (NASDAQ:BIOA - Get Free Report) insider Paul Rubin sold 18,000 shares of the business's stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an...
MarketBeat·3d ago
News Placeholder
Paul Rubin Sells 68,897 Shares of BioAge Labs (NASDAQ:BIOA) Stock
BioAge Labs, Inc. (NASDAQ:BIOA - Get Free Report) insider Paul Rubin sold 68,897 shares of the firm's stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average...
MarketBeat·9d ago
News Placeholder
BioAge Labs (NASDAQ:BIOA) Rating Increased to Hold at Wall Street Zen
Wall Street Zen upgraded BioAge Labs from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·9d ago
News Placeholder
Jefferies Financial Group Inc. Buys Shares of 50,000 BioAge Labs, Inc. $BIOA
Jefferies Financial Group Inc. bought a new stake in BioAge Labs, Inc. (NASDAQ:BIOA - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities...
MarketBeat·14d ago
News Placeholder
BioAge Labs (NASDAQ:BIOA) Issues Quarterly Earnings Results
BioAge Labs (NASDAQ:BIOA - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.56) EPS for the quarter, beating analysts' consensus estimates of ($0.67) by...
MarketBeat·1mo ago
News Placeholder
BioAge Stock Nosedives On Obesity Drug Study Halt: Downgrades Crush Retail Sentiment
BioAge, which had seen strong market interest since its IPO in September amid the weight-loss drug frenzy, is now down over 10% year-to-date.
Stocktwits·1y ago

Latest BIOA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.